Literature DB >> 17054581

Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.

Jian Qiu Sheng1, Tsun Leung Chan, Yee Wai Chan, Ji Sheng Huang, Ji Gui Chen, Ming Zhi Zhang, Xiu Lan Guo, Hong Mu, Annie Sy Chan, Shi Rong Li, Siu Tsan Yuen, Suet Yi Leung.   

Abstract

OBJECTIVE: Hereditary non-polyposis colorectal cancer (HNPCC) syndrome is the most common cause of hereditary colorectal cancer with an early age of onset. Microsatellite instability (MSI) and germline mutation in one of the DNA mismatch repair (MMR) genes are found in the majority of HNPCC families and provide an opportunity for genetic diagnosis and prophylactic screening. The MMR gene mutation spectrum may vary across different populations and be influenced by founder mutations that prevail in specific ethnic groups. China is a big and ancient nation with enormous genetic diversity, which is especially notable between the northern and southern Chinese populations. A MMR gene mutation database for the southern Chinese population based in Hong Kong has been previously established. This study compares the MMR gene mutation spectrum and the MSI of HNPCC between the northern and southern Chinese populations.
METHODS: Twenty-five HNPCC families from northern China were systematically analyzed. The MSI analysis was performed using five loci in the USA National Cancer Institute (NCI) panel (D2S123, D5S346, BAT-25, BAT-26 and BAT-40) by PCR from the tumor and normal tissue. MSH2, MSH6 and MLH1 were performed using immunohistochemical staining. Two founder mutations of MSH2 and MLH1 were examined by PCR base analyses using primers flanking the two deletion sites (c.1452_1455delAATG in MSH2 and 1.8 kb deletion involving exon 11 of MLH1).
RESULTS: Of the 25 families collected, 19 met Bethesda guideline (BG) 1 and six met BG3. Twenty-two (15.7%) were extra-colonic cancers with gastric cancer (in seven patients) being the most common cancer type. Of the 25 tumors analyzed, 21 (84%) were high level microsatellite instability (MSI-H) and four (16%) were microsatellite stable (MSS). Eighteen (86%) of the 21 MSI-H tumors showed loss of either the MLH1 or the MSH2 protein. Three MSI-H tumors and all four MSS tumors showed no loss of expression of the three MMR proteins. Out of the 21 patients with MSI-H tumors, 12 (57%) showed pathogenic germline mutations in either MLH1 (n = 8) or MSH2 (n = 4). Overall, three novel mutations (in patients H22, H17 and H29) have been identified. One of them, c.503_4insA, caused a frameshift mutation in the MLH1 gene. The other two were found in the MSH2 gene, including a frameshift (c.899_890insAT) and a splice junction (IVS7-1G-->A, SA of Exon 8) mutation.
CONCLUSIONS: The results suggest a distinctly different mutation spectrum of MMR genes between northern and southern Chinese populations and call for a systematic, nationwide study to facilitate the design of a MMR gene mutation detection strategy tailored for individual populations in China.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17054581     DOI: 10.1111/j.1443-9573.2006.00269.x

Source DB:  PubMed          Journal:  Chin J Dig Dis        ISSN: 1443-9573


  15 in total

1.  Detection of microsatellite instability in gastric cancer and dysplasia tissues.

Authors:  Bing Li; Hong-Yi Liu; Shao-Hua Guo; Peng Sun; Fang-Ming Gong; Bao-Qing Jia
Journal:  Int J Clin Exp Med       Date:  2015-11-15

2.  The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.

Authors:  Yael Laitman; Liron Herskovitz; Talia Golan; Bella Kaufman; Shani Shimon Paluch; Eitan Friedman
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

3.  Clinical characterization and mutation spectrum in Caribbean Hispanic families with Lynch syndrome.

Authors:  Marcia Cruz-Correa; Yaritza Diaz-Algorri; Julyann Pérez-Mayoral; Wasilah Suleiman-Suleiman; Maria del Mar Gonzalez-Pons; Carlos Bertrán; Nicolás Casellas; Natalia Rodríguez; Sherly Pardo; Keyla Rivera; Rafael Mosquera; Segundo Rodriguez-Quilichini
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Comparison of microsatellite status detection methods in colorectal carcinoma.

Authors:  Mei-Li Chen; Jie-Yu Chen; Jing Hu; Qian Chen; Li-Xia Yu; Bao-Rui Liu; Xiao-Ping Qian; Mi Yang
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

Review 5.  Advances in the study of Lynch syndrome in China.

Authors:  Jun-Yu Lu; Jian-Qiu Sheng
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

6.  Non-truncating hMLH1 variants identified in Slovenian gastric cancer patients are not associated with Lynch Syndrome: a functional analysis report.

Authors:  Matjaz Vogelsang; Radovan Komel
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

7.  Mutation spectrum in HNPCC in the Israeli population.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Michal Sagi; Avital Eilat; Suzan Mendelson; Tamar Hamburger; Aviram Nissan; Ayala Hubert; Luna Kadouri; Eli Pikarski; Israela Lerer; Dvorah Abeliovich; Dani Bercovich; Tamar Peretz
Journal:  Fam Cancer       Date:  2008-04-04       Impact factor: 2.375

8.  Genetic diagnosis strategy of hereditary non-polyposis colorectal cancer.

Authors:  Jian-Qiu Sheng; Hong Zhang; Min Ji; Lei Fu; Hong Mu; Ming-Zhi Zhang; Ji-Sheng Huang; Min Han; Ai-Qin Li; Zhi Wei; Zi-Qin Sun; Zi-Tao Wu; Chang-Hong Xia; Shi-Rong Li
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

9.  Prevalence of pathological germline mutations of hMLH1 and hMSH2 genes in colorectal cancer.

Authors:  Dandan Li; Fulan Hu; Fan Wang; Binbin Cui; Xinshu Dong; Wencui Zhang; Chunqing Lin; Xia Li; Da Wang; Yashuang Zhao
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Missense mutations of MLH1 and MSH2 genes detected in patients with gastrointestinal cancer are associated with exonic splicing enhancers and silencers.

Authors:  Ming Zhu; Hui-Mei Chen; Ya-Ping Wang
Journal:  Oncol Lett       Date:  2013-03-11       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.